Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 2,911 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Noise-induced Hearing Loss
Interventions: EPI-743, Placebo; Drug
Lead sponsor: Edison Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Alzheimer's Disease
Interventions: Placebo, Idalopirdine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 50 Years and older
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 26
States / cities: Mesa, Arizona • Bellflower, California • Costa Mesa, California + 23 more

Conditions: COVID-19
Interventions: Melatonin, Placebo (Methylcellulose) capsule; Drug · Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Obscure Gastrointestinal Bleeding (Occult or Overt)
Interventions: Capsule endoscopy, Dedicated small bowel contrast radiography; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sickle Cell Disease, Sickle-Beta Zero Thalassemia
Interventions: SCD-101; Drug
Lead sponsor: Invenux, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Post Operative Pain, Osteoarthritis, Knee
Interventions: Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release; Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 35 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Migraine, Acute Treatment of Migraine
Interventions: Rimegepant, Placebo, Sumatriptan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,026 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 41
States / cities: Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more

Conditions: Acute Coronary Syndrome
Interventions: TAK-442, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 2,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 15
States / cities: Birmingham, Alabama • Tucson, Arizona • Newark, Delaware + 12 more

Conditions: Menorrhagia
Interventions: Naproxen, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Chicago, Illinois • Seattle, Washington

Conditions: Tardive Dyskinesia
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 49
States / cities: Little Rock, Arkansas • Anaheim, California • Carson, California + 41 more

Conditions: Barrett's Esophagus
Interventions: Secretrol; Drug
Lead sponsor: Effexus Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: HEC585; Drug
Lead sponsor: Sunshine Lake Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Covid19
Interventions: TQ Formula/Tab; Drug
Lead sponsor: Novatek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: San Diego, California • Hialeah, Florida • Houston, Texas

Conditions: Cancer Pain, Quality of Life, Pain, Acute, Cannabis Use
Interventions: PPP001, Placebo; Drug
Lead sponsor: Tetra Bio-Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cave Creek, Arizona

Conditions: Cortical Excitability, Psychiatric Disorder
Interventions: L-theanine, Placebo; Drug
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hip Fractures
Interventions: VK5211, Placebo; Drug
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Yorba Linda, California • Boynton Beach, Florida • Doral, Florida + 4 more

Conditions: Acromegaly
Interventions: octreotide capsules, Matching placebo; Drug
Lead sponsor: Chiasma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 19
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 13 more

Conditions: Post Traumatic Stress Disorder, Alcohol Use Disorder
Interventions: Full Dose MDMA, MDMA-Assisted psychotherapy, Active Placebo Dose MDMA; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: West Haven, Connecticut • Providence, Rhode Island

Conditions: Parkinson's Disease
Interventions: Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa; Drug
Lead sponsor: Novartis; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 21
States / cities: Phoenix, Arizona • Aliso Viejo, California • Irvine, California + 17 more

Conditions: Hypertension
Interventions: Darusentan, Guanfacine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 661 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 85
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 69 more

Conditions: Chronic Pain
Interventions: Tramadol Extended Release Oral Capsule, Benadryl; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions: therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions: TAK-906 Maleate, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 67
States / cities: Dothan, Alabama • Tucson, Arizona • Chula Vista, California + 54 more

Conditions: Pulmonary Arterial Hypertension
Interventions: KAR5585 Capsules, Placebo Capsules; Drug
Lead sponsor: Karos Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: West Bend, Wisconsin

Search by objective public record fields.

Protective Effects of EPI-743 on Noise-Induced Hearing Loss

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding

Dose-Escalation Study of SCD-101 in Sickle Cell Disease

ZYNRELEF for Pain Management in Total Knee Arthroplasty

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

Copper IUD Treatment Observation Study

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants

Safety and Efficacy of Inhaled Cannabis For the Uncontrolled Pain Relief in Patients With Advanced Cancer

Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study

Acute Hip Fracture Study in Patients 65 Years or Greater

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585